Showing results (151-160 of 249) with videos related to

Sort By:
Pageof 25
Cancer|September 26, 1997
De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulinS Jonas, N Rayes, U Neumann, et al.
Transplantation|July 27, 1994
Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506A R Mueller, K P Platz, W O Bechstein, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|March 27, 2001
Portal vein angioplasty using a transjugular, intrahepatic approach for treatment of extrahepatic portal vein stenosis after liver transplantationM Glanemann, U Settmacher, J M Langrehr, et al.
Hepatology (Baltimore, Md.)|August 1, 1997
A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxisU Naumann, U Protzer-Knolle, T Berg, et al.
Hepatology (Baltimore, Md.)|December 1, 1996
Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virionsT Fukumoto, T Berg, Y Ku, et al.
Deutsche Medizinische Wochenschrift (1946)|July 10, 1992
[Liver transplantation in erythrohepatic protoporphyria]T Steinmüller, M O Doss, R Steffen, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|March 29, 2000
[Classification and treatment of bile duct injuries after laparoscopic cholecystectomy]P Neuhaus, S C Schmidt, R E Hintze, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
Recurrence-free survival after liver transplantation for small hepatocellular carcinomaW O Bechstein, O Guckelberger, N Kling, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 31, 2016
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL studyC-H Köhne, G Poston, G Folprecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2005
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinomaG Folprecht, M P Lutz, P Schöffski, et al.
Pageof 25